Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viking Therapeutics Inc | VKTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 10.87 | 04:00:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.87 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.68 - 25.7199 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 10.87 | USD |
Viking Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.09B | 100.03M | - | 0 | -68.87M | -0.69 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Viking Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VKTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.71 | 12.20 | 10.66 | 11.19 | 2,579,832 | -0.84 | -7.17% |
| 1 Month | 14.42 | 16.359 | 10.66 | 13.39 | 2,256,941 | -3.55 | -24.62% |
| 3 Months | 15.74 | 16.359 | 10.66 | 14.00 | 1,801,144 | -4.87 | -30.94% |
| 6 Months | 16.825 | 25.7199 | 10.66 | 18.30 | 2,706,418 | -5.96 | -35.39% |
| 1 Year | 2.76 | 25.7199 | 2.68 | 13.58 | 3,096,047 | 8.11 | 293.84% |
| 3 Years | 5.56 | 25.7199 | 2.02 | 10.32 | 1,692,204 | 5.31 | 95.5% |
| 5 Years | 15.32 | 25.7199 | 2.02 | 9.52 | 1,777,203 | -4.45 | -29.05% |
Viking Therapeutics Description
| Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |